Probiotics In Management Research Articles

Efficacy of Probiotics in Overweight and Obesity Control: An Umbrella Review and Subgroup Meta-Analysis.

Numerous primary and secondary studies have consistently demonstrated that probiotics, including lactobacillus and Bifidobacterium, possess a potential anti-obesity effect. However, it is worth noting that some studies have yielded contrasting results. Considering this, our study aims to present a comprehensive overview of published systematic reviews and meta-analyses, focusing on the efficacy and safety of probiotics in managing obesity. To achieve this objective, we conducted an umbrella review following the PRISMA protocol and Cochrane guidelines. We searched databases such as Embase, PubMed, Cochrane Library, and Google Scholar for relevant systematic reviews and meta-analyses published in English, without imposing any date restrictions. Our inclusion criteria encompassed studies evaluating the anti-obesity impact of probiotics, with a specific focus on changes in body mass index (BMI), fat mass percentage (FMP), body weight (BW), and body fat mass (BFM). These studies were meticulously reviewed by two independent reviewers. Our analysis included five systematic reviews and 18 meta-analyses that met the predefined inclusion and exclusion criteria. The meta-analyses revealed statistically significant reductions in the following parameters: BMI, a decrease of 0.30kg/m2 (p < 0.00001, 95% CI - 0.36 to - 0.25); BFM, a reduction of 0.86kg (p < 0.00001, 95% CI - 1.02 to - 0.71); BW, a decrease of 0.59kg (p < 0.00001, 95% CI - 0.74 to - 0.44); and FMP, a substantial decline of 78% (p < 0.00001, 95% CI - 1.02 to - 0.54). In summary, our umbrella review suggests that existing evidence supports the potential benefits of probiotics in managing obesity and overweight. However, it is essential to acknowledge that the credibility of this evidence is somewhat limited due to the inclusion of studies with poor-quality designs and relatively small participant numbers. To establish the true efficacy of probiotics in obesity management, we recommend conducting robust studies involving larger participant cohorts.

Role of Probiotics in COVID-19 Management?

Probiotics as an intestinal microbe regulator, not only improve the ability of the gastrointestinal microbiota to modulate immune activity, but also strengthen the body's immune system, inhibit allergic reactions and has a significant role especially in the anti-viral immunomodulation. Therefore, in patients with COVID-19, the intestinal micro-eco-regulator, represented by probiotics, may be a therapeutic choice. However, there is still a lack of evidence-based studies to support probiotic treatment of patients with COVID-19. New cohort studies and randomized controlled clinical trials to assess the effectiveness of probiotics in the management of COVID-19 are strongly and urgently needed.

Role of probiotics in the management of cervical cancer: An update.

Studies have extensively investigated a variety of health benefits associated with probiotic supplements, which often contain live microorganisms. The effect of probiotic supplements on cancer prevention and on chemotherapy effectiveness and toxicity are major areas that researchers have focused on. Recently, several researchers have concentrated on assessing the efficacy of probiotics in the treatment of cervical cancer, a leading malignancy in gynecology worldwide, especially in developing countries. To date, numerous clinical studies have demonstrated the efficacy of probiotics in preventing cervical cancer, but their dosages, bacterial strains, and duration of therapy are somewhat inconsistent. In this review, we have systematically updated the role of probiotics in cervical cancer management.

Efficacy of Probiotics in Management of Celiac Disease.

ObjectiveThe objective of this study was to interpret any rule of probiotics in the management of celiac disease and apply the results to improve the quality of life of patients with celiac disease if the result comes in favor of probiotics.Materials and methodsIt was a cross-sectional study conducted in the gastroenterology unit of Nishtar Medical University, Multan. A total of 170 children with celiac disease were enrolled in the study and divided into two groups (A and B) using a computer-generated table of random numbers. Group A was given only a gluten-free diet, while group B was given probiotics and a gluten-free diet. The efficacy of probiotics was measured in terms of reduction in stool frequency at the end of the 28 days of treatment. The data was recorded on the datasheet for every individual, and the statical analysis was performed using the Chi-square test. The patients were fully explained about the research purpose, and written consent was taken from them.ResultsThe efficacy of probiotics in children with celiac disease was compared in both groups. Results showed a marked reduction in the frequency of stools to less than half, i.e., 90.59% (n=77) in group B and 63.53% (n=54) in group A. The Chi-Square test resulted in a p-value of 0.000027 showing a significant difference in both groups.ConclusionProbiotics are found to be highly efficient in terms of reduction in diarrhea in celiac disease. Probiotics will improve not only quality of life but also play an essential role in managing celiac disease.

Role of Probiotics for Recurrent UTIs in the Twenty-First Century: a Systematic Review of Literature.

Urinary tract infections (UTIs) are a common problem, especially in women. Recurrent UTIs (rUTIs) are difficult to treat and while prophylactic antibiotics can be an effective strategy, they worsen antimicrobial resistance and incur side effects. We conducted a systematic review of literature to assess the role of probiotics in management of UTIs. All English language articles reporting on randomised trials and cohort studies were selected, while paediatric patients (< 18years) and patients with neurogenic bladders were excluded. A total of 9 articles (772 patients) met the inclusion criteria with a mean age of 34.2years (range 18-65years). A variety of different probiotics were used. Two studies concluded that probiotics could reduce risk of rUTIs; however, the remainder provided inconclusive results. A key advantage demonstrated, however, was the limited side effect profile and tolerance, which allows for good patient compliance with this treatment strategy. There exists only limited clinical evidence to support the role of probiotics in the management of rUTIs, and based on the current evidence, probiotics can be a potential measure to reduce rUTIs, although further randomised studies will help delineate its formal position in the treatment algorithm.

P–623 Comparative preliminary study of LPS, hs CRP and gut bacterial flora of women to support dysbiosis of gut microbiota (DOGMA) as cause of PCOS

Abstract Study question Study the levels of endotoxin lipopolysaccharide , hs-CRP and gut bacterial flora in Polycystic Ovarian Syndrome to support hypothesis of Dysbiosis of Gut Microbiota (DOGMA) as a cause of PCOS Summary answer Increased serum levels of LPS and hs-CRP along with decreased levels of Bifidobacterium and Lactobacilli by quantitative PCR(qPCR) in women with PCOS. What is known already A hypothesis called DOGMA was proposed in the “pathogenesis of PCOS” as follows: (1) Obesity, high Carbohydrate , high fat and low fiber diet creat an intestinal flora imbalance, thus break in the intestinal epithelium, thus raising the permeation of the intestinal mucosa; 2) That cause lipopolysaccharide (LPS) to leak into the circulation and the subsequent activation of the immune system may affect the functioning of the insulin receptor resulting in insulin resistance; 3) IR/Hyperinsulinemia can facilitate testosterone synthesis, thus interfering with follicular development. Study design, size, duration A descriptive pilot observational study was carried from 1st February 2018 to 31 Dec 2019. The objectives of was to establish and compare basal serum levels of LPS and hs-CRP in 40 women with PCOS ( as per modified Rotterdams Criteria ) and control group of 40 fertile women and also to determine levels of Bifidobacterium and Lactobacilli by quantitative PCR (qPCR) in these two groups. Participants/materials, setting, methods A total of 80 consenting women underwent sonographic , laparoscopic and hormonal evaluation and were grouped into 40 with PCOS as per Rotterdams criteria and 40 healthy control group. The blood samples were taken for estimating hsCRP and LPS. The stool samples were also collected in transport medium and refrigerated . The qPCR was run on stool sample to determine levels of Bifidobacterium and Lactobacillus. The results obtained are compared and presented. Main results and the role of chance The mean age, weight, height and BMI in PCOS ( Grp 1 ) was comparable with controls group( Grp 2). Annovulation (33/40) was more prevalent in PCOS group along with bulky ovaries with raised ovarian volume ( Rt 12.86±2.25 mm, / Lt 12.77±1.43 mm.) . The mean serum FSH (4.51±0.95 / 4.80±0.81) were comparable between groups.The serum LH (10.56±1.28/ 5.18±1.19), AMH (7.72±1.62/ than group 2/ 4.77±1.10) and serum testosterone levels (39.39±7.47/20.46±3.09), were found to be increased in Grp 1 The hs-CRP ( 2.68±0.61/ 1.40±0.52 )and LPS levels 14.95±1.97/ 11.35±1.63) were significantly increased in Grp 1 ,while abundance of Bifidobacterium, and lactobacillus ( 4.39±0.80 &amp; 4.33±1.11) in the control group as compared with the PCOS group (2.10±0.51 and 2.20±0.65) was also noted. The raised hs-CRP ( a non specific marker of inflammation ), raised endotoxin Lipopolysaccharide ( secreted by Gram negative bacteria which leak and react with receptors may cause inflammation in PCOS), and quantitative decreased bacterial load of Bifidobacterium, and lactobacillus as estimated by quantitative PCR in infertile women with PCOS and that of fertile women support dysbiosis as cause of PCOS. Limitations, reasons for caution The study was carried out on population with traditional high prevelance of diorrheal and other infective diseases which might confound the results given ibid. Addition of treatment arm with probiotics y a large multicentric study will give further insight to the dysbiosis and PCOS Wider implications of the findings: The study elaborates the effect of dysbiosis as cause of PCOS and gives direction for alternative strategies like probiotics in management of PCOS. Trial registration number Not applicable

The efficacy of probiotics in management of recurrent aphthous stomatitis: a systematic review and meta-analysis

There is currently a lack of effective drugs to cure recurrent aphthous stomatitis. This study aimed to evaluate the efficacy of probiotics alone or as an adjunct in recurrent aphthous stomatitis (RAS) patients. Seven randomized controlled trials (RCTs) were included, of which three were included in quantitative analysis. Of five studies evaluating the efficacy of probiotics alone compared with placebo or Oracure gel, two reported no significant difference in relieving oral pain, while probiotics exhibited a higher capacity for decreasing oral pain in the other three. A significant decrease in ulcer severity was found in one, while no significant difference was found in the other four. The remaining two studies demonstrated that probiotics, as an adjunct to steroids or anaesthetic antiseptic gel, significantly reduced the ulcer severity and oral pain. The meta-analysis showed a significant decrease in oral pain (− 1.72, P = 0.0001) with probiotics compared with placebo. In conclusion, probiotics alone were capable of relieving oral pain but not effective in reducing ulcer severity. A combination of probiotics and steroids or anaesthetic antiseptic gel was more effective than steroids or anaesthetic antiseptic gel alone in RAS patients. Probiotics are promising for the treatment of recurrent aphthous stomatitis.

Probiotics: Promise, Evidence, and Hope

Probiotics: Promise, Evidence, and Hope

Gastrointestinal Involvement in Systemic Sclerosis: An Update.

Gastrointestinal Involvement in Systemic Sclerosis: An Update.

Does probiotic supplementation affect pulmonary exacerbation and intestinal inflammation in cystic fibrosis: a systematic review of randomized clinical trials.

Patients with cystic fibrosis (CF) usually have abnormal intestinal microbiota due to massive exposure to antibiotics. Probiotics could modify the gut microbiota and hence may affect CF management. So the aim of present systematic review was evaluation of the efficacy and safety of probiotic supplementation for the management of cystic fibrosis. We searched PubMed, Science Direct, Google Scholar, Springer Cochrane Library Databases until January 2016 for randomized controlled trials (RCTs) performed in pediatric or adult populations related to the study aim. Key words were selected based on Mesh terms. Based on the Critical Appraisal Skills Programme checklist, eligibility of included articles was evaluated. Five studies included in this review represent 188 participants with a follow up period ranging from 1 month to 6 months. The results of the included studies supporting the use of probiotics in management of pulmonary exacerbation and intestinal calprotectin in patients with cystic fibrosis. However the level of evidence was limited. The lack of high quality RCTs makes it impossible to support a general recommendation about the use of probiotics in the treatment of CF pulmonary exacerbation and intestinal inflammation.

A study of efficacy of oral probiotics in management of cases with symptomatic white discharge per vagina in a tertiary care hospital

Background: Urogenital infections are the most common gynecological condition constituting about 25% of outpatients. Because of higher recurrence rates and resistance to standard antimicrobials now a days the use of probiotics in augmenting normal bacterial populations is gradually achieving scientific acceptance. Objective: Determine the efficacy of probiotics in treating women with symptomatic white discharge per vagina (WDPV), role of oral probiotics in restoring the vaginal flora. Methods: 70 women aged between 18 to 45 yrs (mean age 35yrs) with symptomatic WDPV who are attending gynecology outpatient procedures, these patients underwent Grams stain, received antibiotics along with probiotics (L. rhamnosus GR-1 and L. fermentum RC-14) for a period of 1 week, again reviewed with repeat Grams stain. Results: Among post-treatment group 46 % of patients showed &gt;30 organisms/100× objective. Fifty percent of patients showed counts between 5 and 30 among post-treatment, but the response in terms of symptomatic relief was about 74%. The improvement in the lactobacilli count was interpreted using Nugents scoring. Conclusion: The combination of probiotic (L. rhamnosus GR-1 and L. fermentum RC-14) is not only safe for daily use in healthy women, but it can reduce colonization of the vagina by potential pathogenic bacteria and yeast.

Probiotics for the management of type 2 diabetes mellitus: A systematic review and meta-analysis

AimsTo systematically review evidence of probiotic interventions against type 2 diabetes mellitus (T2DM) and analyse the effects of probiotics on glycaemic control among T2DM patients. MethodsElectronic search using five electronic databases was performed until October 2015. Relevant studies were identified, extracted and assessed for risk of bias. The primary outcomes of this review were glycated haemoglobin (HbA1c) and fasting blood glucose (FBG). Fasting plasma insulin, homeostasis model assessment-insulin resistance, C-reactive protein, interleukin-6 and malondialdehyde, were identified as the secondary outcomes. Mean differences (MD) between probiotics and control groups for all outcomes were pooled using either Fixed- or Random-Effect Model. Statistical heterogeneity was assessed using I2 and Chi2 tests. ResultsSix randomised controlled trials (RCTs) were included in the systematic review, whereas only five were included in meta-analysis. Most RCTs were presented with low or unclear risk of bias. When compared to placebo, FBG was significantly lower with probiotic consumption (MD=−0.98mmol/L; 95% CI: −1.17, 0.78, p<0.00001), with moderate but insignificant heterogeneity noted. Insignificant changes between the groups were also noted for HbA1c and other secondary outcomes. ConclusionsA moderate hypoglycaemic effect of probiotics, with a significantly lower FBG was noted. Findings on HbA1c, anti-inflammatory and anti-oxidative effects of probiotics in the clinical setting, however, remain inconsistent. The findings imply the need for well-designed clinical studies to further assess the potential beneficial effects of probiotics in management of T2DM.

Probiotics in management of hepatic encephalopathy.

Gut microflora leads to production of ammonia and endotoxins which play important role in the pathogenesis of hepatic encephalopathy (HE). There is relationship between HE and absorption of nitrogenous substances from the intestines. Probiotics play a role in treatment of HE by causing alterations in gut flora by decreasing the counts of pathogen bacteria, intestinal mucosal acidification, decrease in production and absorption of ammonia, alterations in permeability of gut, decreased endotoxin levels and changes in production of short chain fatty acids. Role of gut microbiota using prebiotics, probiotics and synbiotics have been evaluated in the management of minimal hepatic encephalopathy (MHE), overt HE and prevention of HE. Many studies have shown efficacy of probiotics in reduction of blood ammonia levels, treatment of MHE and prevention of HE. However these trials have problems like inclusion of small number of patients, short treatment durations, variability in HE/MHE related outcomes utilized and high bias risk, errors of systematic and random types. Systematic reviews also have shown different results with one systematic review showing clinical benefits whereas another concluded that probiotics do not have any role in treatment of MHE or HE. Also practical questions on optimal dose, ideal combination of organisms, and duration of treatment and persistence of benefits on long term follow-up are still to be clarified. At present, there are no recommendations for use of probiotics in patients with HE.

Liver Diseases: The Role of Gut Microbiota and Probiotics

There is unique co-ordination between gut and liver; portal venous blood derived from the mesenteric venous circulation constitutes approximately 75% of total hepatic blood flow and its content activates multiple liver functions. Intestinal microbiota plays an important role in health and disease. The gut-liver axis provides interaction between microbial components and liver causing liver damage. Bacterial overgrowth, dysfunctional immunity, altered intestinal permeability are implicated in pathogenesis of infections, hepatic encephalopathy, spontaneous bacterial peritonitis and hepatorenal syndrome etc. Probiotics may prevent these abnormal interactions between gut and liver by improving intestinal barrier function and prevention of bacterial translocation. This review addresses gut-liver axis, gut microbiota in liver disease and probiotics in management of liver diseases.

Use of Probiotics for Management of Acute Gastroenteritis

Use of Probiotics for Management of Acute Gastroenteritis

Bağırsak mikroflorasının inflamatuvar hastalık patogenezindeki yeri

Degisime ugramis mikroflora(disbiyoz) insanlarda pek cok hastaliklar ile iliskilidir. Bugunlerde mikrofloranin yasam stili, beslenme kaynaklarindaki degisime adapte olamadigi durumlarda yillar icinde immun bozukluklarin gelismesinden sorumlu tutulmaktadir. Dis cevreden bagimsiz ve antibiyotik tedavili hayvan model calismalari da hastaliklara yatkinlikta intestinal bakterilerin sorumlu olabilecegini desteklemektedir. Probiyotikler bagirsak ortamina aktif durumda yeterli miktarda ulastiklarinda saglikli etkiler olusturabilen etkin mikroorganizmalar olarak tanimlanmaktadir. Hastaliklarin kontrolunde bu probiotiklerin kullanabilirligi gercegi ve secenegini arastirmak amacli calismalar yapilmistir. Probiotikler, intestinal flora dengesizliginde ve disbiyozun neden oldugu hastaliklarda kullanilabilecek gecerli bir tedavi metodu olarak bu calismalarin bulgularinca desteklenmektedir.

Метаболические пробиотики в лечении острых кишечных инфекций ротавирусной этиологии у детей

Метаболические пробиотики в лечении острых кишечных инфекций ротавирусной этиологии у детей

Clinical potential for the use of probiotics in the management of respiratory conditions and cold- and influenza-like symptoms

Clinical potential for the use of probiotics in the management of respiratory conditions and cold- and influenza-like symptoms Matthias Volkmar Kopp1, Tobias Ankermann2, Christoph H&auml;rtel11Klinik f&uuml;r Kinder und Jugendmedizin University L&uuml;beck, L&uuml;beck, Germany; 2Klinik f&uuml;r Allgemeine P&auml;diatrie, Christian-Albrechts-University Kiel, GermanyAbstract: Respiratory conditions including complaints like cough, rhinitis, sinusitis, or influenza-like symptoms are commonly summarized as acute upper respiratory tract infections (URTIs). The mechanisms of the potential beneficial effects of probiotics in the management of URTIs are not completely elucidated. Possible explanations are any or all of the following: 1) probiotics compete against other pathogens for colonization of the upper respiratory tract, 2) probiotics increase the barrier function, and 3) probiotics directly cause immunomodulatory effects. Here we review the current evidence for the use of probiotics in the clinical management of URTIs in different age groups. Animal studies and in vitro data reveal that probiotics might have clinical potential in the management of URTIs. In contrast, data from double-blind placebo-controlled clinical trials show conflicting results. Given the current level of evidence, it is therefore not appropriate to recommend probiotics as a part of standard therapy or for the management of URTIs.Keywords: probiotics, prevention, infection, respiratory tract, asthma, children

Role of probiotics in management of diverticular disease

Patients with diverticular disease may experience a variety of chronic symptoms, including abdominal discomfort, bloating, and altered bowel habit. They are also at risk of complications, including hemorrhage, diverticulitis, abscess, and fistula formation. The potential role of abnormal colonic microflora in the pathogenesis of diverticular inflammation has led to investigation of novel therapies such as probiotics. Probiotics are microorganisms that may be of net benefit to humans when consumed. The rationale and safety of their use in diverticular disease is discussed and current literature is reviewed.

A Review and Meta-analysis of the Efficacy of Antibiotics and Probiotics in Management of Pouchitis

A Review and Meta-analysis of the Efficacy of Antibiotics and Probiotics in Management of Pouchitis